Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

BADBIR Study Group

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science